通用流感疫苗研究进展  

Research progress on universal influenza vaccine

作　　者：赵淑敏 陈继军 ZHAO Shu-min;CHEN Ji-jun(The Fifth Research Department,Lanzhou Institute of Biological Products Co.,Lid.,Center for Gansu Provincial Vaccine Engineering Research,Lanzhou 730046,Gansu Province,China)

机构地区：[1]兰州生物制品研究所有限责任公司第五研究室、甘肃省疫苗工程技术研发中心,甘肃兰州730046

出　　处：《微生物学免疫学进展》2023年第2期60-68,共9页Progress In Microbiology and Immunology

摘　　要：流行性感冒病毒(influenza virus,简称流感病毒)是一种严重威胁人类健康的病毒。全世界每年有上万人死于流感病毒引起的流行性感冒(influenza,简称流感)。同时,流感也对全球经济发展产生严重影响。接种流感疫苗(influenza vaccines)是流感防控的重要手段之一。流感病毒亚型众多、抗原变异较快且因其流行趋势难以预测等因素导致传统流感疫苗接种后免疫效果不佳,研发通用流感疫苗成为预防流感的一种理想策略。现对以流感病毒血凝素(hemagglutinin, HA)、神经氨酸酶(neuraminidase, NA)及流感病毒其他结构蛋白保守区域为免疫原的通用流感疫苗的研究进展作一概述。Influenza virus is a severe threat to human health. Tens of thousands of deaths worldwide are caused by influenza each year. At the same time, the flu has a severe impact on global economic development. Influenza vaccines are one of the most important methods for influenza prevention and control. Due to the numerous subtypes of influenza viruses, rapid antigenic variation and unpredictable epidemic trend, etc, the immune effect of traditional influenza vaccination is not satisfied. The development of universal influenza vaccine has thus become an ideal strategy to prevent influenza. This article reviews the research progress on the conserved regions of hemagglutinin(HA), neuraminidase(NA) and other structural proteins of influenza virus in the development of universal influenza vaccines.

关 键 词：流行性感冒病毒 通用流感疫苗 交叉保护 细胞免疫 血凝素 神经氨酰酶 T细胞反应 

分 类 号：R393[医药卫生—基础医学]